A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine

The objective of this study was to evaluate patients’ satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1–3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting <3 months. At study end patients assigned preference to one of the treatments using a questionnaire with a score from 0 to 5 (primary endpoint). Secondary endpoints were pain free and pain relief episodes at 2 and 4 h, and recurrent and sustained pain free episodes within 48 h. Of the 133 patients (86%, intention-to-treat population) 114 of them expressed a preference for a triptan. The average preference score was not significantly different between frovatriptan (3.1 ± 1.3) and almotriptan (3.4 ± 1.3). The rates of pain free (30% frovatriptan vs. 32% almotriptan) and pain relief (54% vs. 56%) episodes at 2 h did not significantly differ between treatments. This was the case also at 4 h (pain free: 56% vs. 59%; pain relief: 75% vs. 72%). Recurrent episodes were significantly (P < 0.05) less frequent under frovatriptan (30% vs. 44%), also for the attacks treated within 30 min. No significant differences were observed in sustained pain free episodes (21% vs. 18%). The tolerability profile was similar between the two drugs. In conclusion, our study suggests that frovatriptan has a similar efficacy of almotriptan in the short-term, while some advantages are observed during long-term treatment.

[Modern methods of neurovisualization and preventive treatment of migraine]

Forty-eight patients have been examined in the Centre of Headache Treatment. MRI of the brain revealed the changes in the white matter in 69% of patients, 39% had multiple foci (more than 3). The largest number of foci was seen in patients with frequent and chronic migraine without aura, but not in those with migraine with aura. The foci were located more often in frontal areas and less often in parietal and temporal areas. Twenty-three patients with frequent and chronic migraine received the preventive treatment with the anticonvulsant topiramate (topamax, capsules 25 and 50 mg). The duration of treatment was from 4 to 12 months depending on the disease severity. The decrease in frequency of migraine attacks was seen after 1 month of the treatment. After 6 months, mean score on the MIDAS decreased from 26.5 that indicated the severity of migraine and significant decrease in working capacity to 5.7 that corresponded to the mild form of migraine.

Topiramate responsive exploding head syndrome

Exploding head syndrome is a rare phenomenon but can be a significant disruption to quality of life. We describe a 39-year-old female with symptoms of a loud bang and buzz at sleep onset for 3 years. EEG monitoring confirmed these events occurred in transition from stage 1 sleep. This patient reported improvement in intensity of events with topiramate medication. Based on these results, topiramate may be an alternative method to reduce the intensity of events in exploding head syndrome.

[Temporal characteristics of migraine-type headache]

OBJECTIVES

Migraine is characterized by headache attacks, and symptoms belong to various organ systems. Temporal characteristics of headache must be known to prescribe the appropriate drug for the treatment of migraine attacks. In this study, we aimed to reveal the temporal characteristics of headache and to search whether or not these characteristics differ in patient subgroups in migraineurs admitted to a tertiary health center.

METHODS

Consecutive adult migraineurs who admitted to the Headache Section of Kocaeli University Faculty of Medicine Research Hospital involved the study. Their demographical data, medical history and temporal characteristics of headaches were questioned.

RESULTS

Thirty (19.6%) patients among the 153 migraineurs involved had chronic daily headache. Headaches were detected to reach the maximum pain intensity within 2 hours in 34 patients (22.2%) and to continue over 24 hours in 87 (56.9%) patients. Patients with headaches lasting over 24 hours had a greater mean age than of those with headaches ending within 24 hours (40.8+/-12.4 and 36.2+/-11.4, respectively; p=0.019). The mean disease age of the patients with headaches lasting over 24 hours was also greater than of the group with headaches ending within 24 hours.

CONCLUSION

Our study revealed that temporal characteristics of headache may differ in patient subgroups in adult migraineurs. Further studies with large populations are warranted to verify these results and determine which temporal characteristics are common in which patient subgroups.

Perceptive aspects of visual aura

Visual aura is the most common feature associated with migraine, though it can occur separately. In both cases it often represents a dramatic event, especially for patients who experience it for the first time. Besides, its subjective characteristics may illuminate on the functional architecture of the visual cortex. Repetitive events of migraine and visual aura have been suggested to affect the visual system in the long run, both on the cortical and precortical level. In effect, objective investigation of visual functions in patients support the idea that a selective damage does occur, so that more attention to visual examination seems to be justified. In this paper, subjective and psychophysical aspects of visual aura are examined, lastly highlighting and discussing the interesting correlations found between this condition and normal-tension glaucoma.

CADASIL presenting as status migrainosus and persisting aura without infarction

Different types of migraine have been reported in 20-40% of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). We describe a novel migrainous manifestation of CADASIL consisting in status migrainosus and persistent aura without infarction. The symptoms resolved after i.v. treatment with lorazepam and mannitol.

[Cortical spreading depression (CSD): a neurophysiological correlate of migraine aura]

Cortical spreading depression (CSD) is a transient (60-120 s) and at 3-5 mm/min propagating depolarization wave of cortical neurons and glial cells and is characterized by a DC shift of 20-35 mV. It is accompanied by massive redistribution of ions between extracellular and intracellular compartments and by a water influx into the cells. Extracellular potassium ion concentration increases up to 60 mM/l. Potassium ions and the excitatory neurotransmitter glutamate essentially contribute to the initiation and propagation of CSD. Both depolarization and disturbance of brain ion homeostasis regenerate within a few minutes while enhancing energy metabolism, but do not cause damage to normally perfused brain tissue. The similar propagation velocity of CSD and visual scotoma during migraine aura led to the assumption that CSD could be the underlying mechanism of migraine aura. The observation of CSD waves in migraine aura patients with the magnet encephalogram (MEG) technique confirmed this theory. Although many data support the relationship between CSD and aura phase in migraine, the role of CSD in migraine headache is still disputed.

Influence of physiologic hormonal modification and of hormonal treatment in a patient with a history of migraine with aura

We present the case of 48-year-old woman suffering from migraine with aura (MA) since menarche. During her life the patient frequently presented catamenial MA attacks with an increasing frequency during pregnancy in particular in the second and third trimesters, and then during breast-feeding. Treatment with oral contraceptive (OC) for endometriosis and later with cyclophosphamide, methotrexate, fluorouracil (CMF) for breast cancer produced a higher number of attacks. Instead, she referred an improvement with gonadotropin releasing hormone agonist (GnRH-a) for the treatment of endometriosis and then with tamoxifen as hormonal therapy after mastectomy and chemotherapy for breast cancer. We highlight the importance of physiological hormonal modification and hormonal therapies on the course of MA.

Hemiplegic migraine: hyperperfusion and abortive therapy with intravenous verapamil

A 20-year-old female with hemiplegic migraine was treated during an acute attack with intravenous verapamil, which reproducibly resolved the headache within 20 min but did not affect her hemiplegia. Magnetic resonance (MR) and computed tomographic (CT) angiography and perfusion performed during the attack showed vasodilation and hyperperfusion. Cerebral hyperperfusion concurrent with hemiplegia suggests a dissociation between cerebral perfusion and neuronal function in hemiplegic migraine. The beneficial effect of verapamil on headache but not hemiplegia suggests a distinct mechanism for pain and neuronal dysfunction in hemiplegic migraine, with the beneficial effect on pain not due to vasodilation.